MX2023002570A - Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer. - Google Patents
Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.Info
- Publication number
- MX2023002570A MX2023002570A MX2023002570A MX2023002570A MX2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonist
- cancer
- vegfr
- breast cancer
- combination therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title abstract 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 229940124060 PD-1 antagonist Drugs 0.000 title 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 206010055113 Breast cancer metastatic Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción describe terapias de combinación que comprenden un antagonista de receptor de muerte celular programada 1 (PD-1) y un antagonista del receptor 2 del factor de crecimiento endotelial vascular (VEGFR-2), y el uso de las terapias de combinación para el tratamiento de un cáncer; en una modalidad, el cáncer es un glioblastoma, un cáncer de mama, un cáncer de mama triple negativo, un cáncer de mama metastásico, o un cáncer de mama triple negativo metastásico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073512P | 2020-09-02 | 2020-09-02 | |
| US202063122321P | 2020-12-07 | 2020-12-07 | |
| PCT/IB2021/058043 WO2022049526A1 (en) | 2020-09-02 | 2021-09-02 | Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002570A true MX2023002570A (es) | 2023-05-19 |
Family
ID=77914405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002570A MX2023002570A (es) | 2020-09-02 | 2021-09-02 | Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230265196A1 (es) |
| EP (1) | EP4208482A1 (es) |
| JP (1) | JP2023540490A (es) |
| KR (1) | KR20230087451A (es) |
| AU (1) | AU2021337223A1 (es) |
| CA (1) | CA3189987A1 (es) |
| MX (1) | MX2023002570A (es) |
| WO (1) | WO2022049526A1 (es) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE69942671D1 (de) | 1998-12-01 | 2010-09-23 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| ES2362931T3 (es) | 2002-03-04 | 2011-07-15 | Imclone Llc | Anticuerpos humanos específicos contra kdr y usos de los mismos. |
| PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
| ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| SI2691112T1 (en) | 2011-03-31 | 2018-07-31 | Merck Sharp & Dohme Corp. | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH |
| KR20190133790A (ko) | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| RU2723050C2 (ru) | 2013-05-02 | 2020-06-08 | Анаптисбайо, Инк. | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) |
| CN105683217B (zh) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | 与pd-1结合的抗原结合蛋白 |
| HRP20221262T1 (hr) | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20190183972A1 (en) * | 2016-06-03 | 2019-06-20 | Imclone Llc | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
-
2021
- 2021-09-02 JP JP2023514117A patent/JP2023540490A/ja active Pending
- 2021-09-02 AU AU2021337223A patent/AU2021337223A1/en active Pending
- 2021-09-02 US US18/043,602 patent/US20230265196A1/en active Pending
- 2021-09-02 KR KR1020237010758A patent/KR20230087451A/ko unknown
- 2021-09-02 WO PCT/IB2021/058043 patent/WO2022049526A1/en active Application Filing
- 2021-09-02 CA CA3189987A patent/CA3189987A1/en active Pending
- 2021-09-02 MX MX2023002570A patent/MX2023002570A/es unknown
- 2021-09-02 EP EP21777846.3A patent/EP4208482A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3189987A1 (en) | 2022-03-10 |
| US20230265196A1 (en) | 2023-08-24 |
| JP2023540490A (ja) | 2023-09-25 |
| WO2022049526A1 (en) | 2022-03-10 |
| KR20230087451A (ko) | 2023-06-16 |
| EP4208482A1 (en) | 2023-07-12 |
| AU2021337223A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meng et al. | Pericytes: a double-edged sword in cancer therapy | |
| Singh et al. | Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study | |
| Naoum et al. | The impact of chest wall boost on reconstruction complications and local control in patients treated for breast cancer | |
| WO2020176693A3 (en) | Methods for treating map3k8 positive cancers | |
| MX2020008395A (es) | Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. | |
| Russe et al. | Autologous fat grafting for enhancement of breast reconstruction with a transverse myocutaneous gracilis flap: a cohort study | |
| Vitzthum et al. | Comparison of hematologic toxicity and bone marrow compensatory response in head and neck vs. cervical cancer patients undergoing chemoradiotherapy | |
| Sayan et al. | Hypofractionated postmastectomy radiation therapy | |
| MX2023002570A (es) | Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer. | |
| Wobb et al. | Comparison of chronic toxicities between brachytherapy-based accelerated partial breast irradiation and whole breast irradiation using intensity modulated radiotherapy | |
| TW200610555A (en) | Extended treatment of tumors through vessel occlusion with light activated drugs | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| MX2023003032A (es) | Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer. | |
| Maroun et al. | Locally advanced cervical cancer in renal transplant patients: a dilemma between control and toxicity | |
| Prado et al. | Adyuvant fractionated radiotherapy after resection of intracranial hemangiopericytoma | |
| Flynn | Higher dose radiotherapy trial halves treatment time | |
| Chargari et al. | No evidence of increased skin toxicity with aromatase inhibitors and concurrent hypofractionated radiation therapy in menopausal breast cancer patients | |
| Gangegowda et al. | A new cannula for suction removal of parenchymal tissue of gynaecomastia | |
| Vargo et al. | Gynecologic Brachytherapy: Vaginal Cancer | |
| Miri Hakimabad et al. | EP-2145 Biological comparison of 60 Co & 192 Irbrachytherapy sources: a possible need for correction factor | |
| Starr | Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations. | |
| Hauge et al. | PO-0984: Combined inhibition of Chk1 and Wee1 kinases for cancer treatment | |
| CN105218647A (zh) | Vegfr2阻断剂多肽及其应用 | |
| Chien et al. | Implantable Oxygen Biosensor Reveals Post-Occlusion Tissue Reactive Hyperoxia | |
| Doyle | Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer. |